Diabetes and obesity drug access remains a Thursday cost story as GLP-1 demand collides with prior authorization and supply management. Endocrinologists report patients stretching doses; insurers tighten criteria.

Backstory: blockbuster demand outran manufacturing. Watch FDA shortage lists and payer bulletins. Agree access is uneven; differ on whether employers should cover obesity indications broadly.

As of Thursday, October 1, the public record on “Diabetes drug access still a cost and supply puzzle” still matches the facts above. Health coverage stays practical: what agencies advise, what patients can do, and where doctors still disagree. Reporting from FDA, Associated Press anchors the Sources list; this card does not invent tallies, quotes, or outcomes beyond what those links support.

For a reader new to the thread: GLP-1 demand continues to strain coverage rules. Patients report pharmacy runarounds for maintenance doses. Readers can follow the linked Sources for the latest confirmed detail on Thursday. A short history beat matters here — prior seasons, rulings, product cycles, or diplomatic rounds set up today’s stakes — so the same-day news sits in context without filler. When the story is still moving, the copy states what is locked and what remains unsettled.

Where coverage lines up, FDA shortage tracking and AP health reporting agree GLP-1 access remains constrained for many patients. Where accounts still diverge, Manufacturers cite scaling; patients cite denied claims and empty shelves. Putting the shared facts and the plain-language split side by side lets readers judge the next development for themselves.

CDC, FDA, and clinician society pages remain the practical places for shot clinics, shortages, and seasonal risk. If a timed hearing, print, game, or court deadline is attached, later updates should wait for confirmation from at least two independent outlets before treating an outcome as final. Until then, treat this wording as the careful Thursday morning baseline, not a prediction.